Shire PLC (LON:SHP)‘s stock had its “outperform” rating restated by equities researchers at BNP Paribas in a note issued to investors on Friday. They currently have a GBX 5,900 ($77.01) target price on the biopharmaceutical company’s stock. BNP Paribas’ price objective indicates a potential upside of 16.58% from the stock’s current price.
A number of other brokerages have also commented on SHP. Deutsche Bank AG reiterated a “buy” rating and issued a GBX 6,000 ($78.32) target price on shares of Shire PLC in a research report on Wednesday, July 13th. Liberum Capital restated a “buy” rating and issued a GBX 5,500 ($71.79) price objective on shares of Shire PLC in a research report on Friday, July 29th. Goldman Sachs Group Inc. restated a “conviction-buy” rating and issued a GBX 6,300 ($82.23) price objective on shares of Shire PLC in a research report on Thursday. Berenberg Bank restated a “buy” rating and issued a GBX 5,800 ($75.71) price objective on shares of Shire PLC in a research report on Wednesday, July 6th. Finally, Shore Capital restated a “buy” rating on shares of Shire PLC in a research report on Friday, July 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Shire PLC has a consensus rating of “Buy” and an average price target of GBX 5,828 ($76.07).
Shire PLC (LON:SHP) opened at 5000.00 on Friday. The stock’s market capitalization is GBX 34.14 billion. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00. The company has a 50 day moving average of GBX 4,985.30 and a 200-day moving average of GBX 4,508.27.
The firm also recently declared a dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 8th will be issued a dividend of GBX 3.51 ($0.05) per share. This represents a dividend yield of 0.07%. The ex-dividend date of this dividend is Thursday, September 8th.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.